Clinical Trials Logo

Clinical Trial Summary

We propose to analyze a DNA sample for mutations in the estrogen receptor gene from a patient who appears insensitive to estrogen hormone treatment.


Clinical Trial Description

We propose to analyze a DNA sample for mutations in the estrogen receptor gene from a patient who appears insensitive to estrogen hormone treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00342498
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date January 12, 1994
Completion date June 17, 2008

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05022992 - Effects of a Single Bout of Resistance Training Session on Hormonal Response in Pre-pubertal and Pubertal Boys N/A
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Completed NCT04862208 - Breakfast Consumption and Energy Balance in Active Adult Males N/A
Recruiting NCT01121783 - The Effect of Lactisole on the Responses to Glucose Solution N/A
Completed NCT03677336 - Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI Phase 4
Completed NCT04414488 - The Impact of Regional Anaesthesia on Hormone Levels in Thoracic Surgery.
Completed NCT04930224 - Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients
Completed NCT02858336 - CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study) N/A
Completed NCT05136742 - Aerobic Exercise With Diet Induces Hormonal, Metabolic, and Psychological Changes N/A
Recruiting NCT04326374 - Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency Phase 3
Completed NCT02781727 - A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) Phase 3
Active, not recruiting NCT05288166 - A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Phase 3